Intravenous Ketamine Infusion on Postoperative Analgesia of Living Liver Donors

Sponsor
Inonu University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05441150
Collaborator
(none)
2
1
2
5
0.4

Study Details

Study Description

Brief Summary

Because of the insufficiency of cadaveric organs and increasing need for organs, the interest in living donor liver transplantation have been greatly increased. The relative reduction of the remaining liver after the operation in Living Liver Donors makes it difficult and compelling to choose a very effective and very safe method in the management of postoperative analgesia.

Opioids are the main agents used in the postoperative analgesia of Live Liver Donors. Opioids have serious side effects such as respiratory depression, apnea, circulatory collapse, coma, and death. Both short-term and long-term administration of opioids cause acute opioid-induced hyperalgesia.

Ketamine, an NMDA receptor antagonist, has been hypothesized to counter opioid tolerance and NMDA receptor-mediated central sensitization. Various studies and systematic reviews have shown that low-dose ketamine has an opioid-sparing effect in all surgical patients.

Although low-dose ketamine has been shown to be beneficial overall in relieving pain, it is unclear whether it has an identified benefit in hepatectomy cases. The aim of this clinical trial was to evaluate the effect of low-dose ketamine administration on postoperative analgesia in living donor liver donors undergoing right hepatectomy procedure.

Condition or Disease Intervention/Treatment Phase
  • Drug: Low dose ketamine infusion
  • Drug: 0.9% NaCl infusion
Phase 4

Detailed Description

Liver transplantation is the only treatment for end-stage liver failure. The insufficiency of cadaveric organs and the inability to meet the increasing need for organs with cadaveric transplantations have greatly increased the interest in living donor liver transplantation. The relative reduction of the remaining liver after the operation in Living Liver Donors makes it difficult and compelling to choose a very effective and very safe method in the management of postoperative analgesia.

Opioids are the main agents used in the postoperative analgesia of Live Liver Donors. Opioids have serious side effects such as respiratory depression, apnea, circulatory collapse, coma, and death. Both short-term and long-term administration of opioids cause acute opioid-induced hyperalgesia.

There is evidence that opioid tolerance can occur in the dorsal root ganglion through N-methyl-D-aspartate (NMDA) receptor activation. Ketamine, an NMDA receptor antagonist, has been hypothesized to counter opioid tolerance and NMDA receptor-mediated central sensitization. Low-dose ketamine is an effective adjuvant in painful orthopedic procedures that reduces pain and opioid need, especially in the first 24 hours after the procedure. Various studies and systematic reviews have shown that low-dose ketamine has an opioid-sparing effect in all surgical patients.

Although low-dose ketamine has been shown to be beneficial overall in relieving pain, it is unclear whether it has an identified benefit in hepatectomy cases. The aim of this randomized placebo-controlled clinical trial was to evaluate the effect of low-dose ketamine administration on postoperative analgesia in living donor liver donors undergoing a painful right hepatectomy procedure.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Prevention
Official Title:
Effect of Intraoperative Intravenous Ketamine Infusion on Postoperative Analgesia in Right Hepatectomy of Living Liver Donors
Actual Study Start Date :
Jun 1, 2022
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Ketamine Group

Patients who received low-dose ketamine infusion

Drug: Low dose ketamine infusion
Administering low-dose ketamine infusion to the patient under general anesthesia for Ketamine Group.
Other Names:
  • Ketamine
  • Sham Comparator: Control group

    Patients who received 0.9% Sodium Chloride Solution, Intravenous, (NaCl) infusion

    Drug: 0.9% NaCl infusion
    Same dose of 0.9% NaCl infusion as the dose of ketamine for Control Group.
    Other Names:
  • Saline
  • Outcome Measures

    Primary Outcome Measures

    1. Postoperative opioid consumption [24 hour]

      To determine the cumulative opioid consumption at the end of 24 hours in patients who received low-dose ketamine or 0.9% NaCl infusion.

    Secondary Outcome Measures

    1. Postop Sedation Score [Postoperative 1 hour]

      Postop Sedation Score (0-3): sedation was measured on a scale of 0 to 3 0: fully awake; 1: lightly sedated, rarely sleepy and easily aroused; 2: moderately sedated, often sleepy and easily aroused; 3; severely sedated, sleepy and difficult to wake up

    2. postoperative complications [24 hour]

      postoperative complications: pruritus, vomiting, hallucination

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • living liver donors, aged 16-65 years, who are scheduled for right hepatectomy will be included in the study.
    Exclusion Criteria:
    • to use opioid medications before surgery,

    • trauma,

    • body mass index (BMI) >35,

    • unstable ischemic heart disease,

    • increased intracranial or intraocular pressure,

    • lactation,

    • to have an allergic to ketamine, morphine, propofol or remifentanil,

    • psychiatric illness, patient-controlled analgesia (PCA)

    • unwillingness or inability to use the device

    • inability to use the numerical rating scale (NRS).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Inonu university Malatya Turkey 044100

    Sponsors and Collaborators

    • Inonu University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mehmet Ali Erdoğan, Inonu University, School of Medicine, Department of Anaesthesiology and ReanimationMalatya, Turkey, Inonu University
    ClinicalTrials.gov Identifier:
    NCT05441150
    Other Study ID Numbers:
    • Ketamin-Postopanalgesia
    First Posted:
    Jul 1, 2022
    Last Update Posted:
    Jul 5, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by Mehmet Ali Erdoğan, Inonu University, School of Medicine, Department of Anaesthesiology and ReanimationMalatya, Turkey, Inonu University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 5, 2022